MRNA vs. RVMD: Moderna vs. Revolution Medicines Stock Comparison

November 11, 2026

How do Moderna (MRNA) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Moderna (MRNA) and Revolution Medicines (RVMD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Moderna (MRNA) and Revolution Medicines (RVMD)
Profile Item	MRNA	RVMD
Name	Moderna Inc.	Revolution Medicines, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	101.48 billion USD	41.59 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	December 7, 2018	February 13, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MRNA

RVMD

GSPC

Moderna (MRNA) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Moderna (MRNA) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Moderna (MRNA) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
Total Return (1Y)	1,031.66%	224.80%
Total Return (3Y, Annualized)	58.68%	114.71%
Total Return (5Y, Annualized)	3.23%	43.47%

Risk Profile

Drawdown History

MRNA

RVMD

GSPC

Moderna (MRNA) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Moderna (MRNA) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
Volatility (1Y, Annualized)	194.88%	68.29%
Beta (5Y)	1.08	1.42
Max Drawdown (5Y)	-93.93%	-55.71%
Avg. Volume (3M)	21.61M	2.06M

Risk-Adjusted Performance

Risk-Return Positioning

MRNA and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
Sharpe Ratio (1Y)	5.27	3.23
Sortino Ratio (1Y)	20.44	6.92

Profitability

ROE (TTM)

Both Moderna (MRNA) at -39.00% and Revolution Medicines (RVMD) at -93.56% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
MRNA: -39.00%
Q1: -64.05%
Min: -167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
RVMD: -93.56%
Min: -167.77%

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Revolution Medicines (RVMD) reports 0.00%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
MRNA: -141.43%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
RVMD: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Moderna (MRNA) at -557.93% and Revolution Medicines (RVMD) at -188.88% report negative operating margin values, usually indicating operating losses over the period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
MRNA: -557.93%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
RVMD: -188.88%
Min: -207.40%

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
ROE (TTM)	-39.00%	-93.56%
ROA (TTM)	-13.26%	-32.13%
Net Margin (TTM)	-141.43%	0.00%
Operating Margin (TTM)	-557.93%	-188.88%
Gross Margin (TTM)	-66.02%	0.00%

Growth

Revenue Growth

Only one side can be read here: Moderna (MRNA) reports revenue growth of -39.92%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Moderna (MRNA) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
Revenue Growth (YoY)	-39.92%	--
Revenue Growth (3Y CAGR)	-53.30%	--
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MRNA: 2.30
Min: 0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max: 25.13
Q3: 12.13
RVMD: 8.36
Median: 5.52
Q1: 2.47
Min: 0.10

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Moderna (MRNA) at 0.19 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
MRNA: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max: 1.42
Q3: 0.65
RVMD: 0.50
Median: 0.15
Q1: 0.02
Min: 0.00

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
Current Ratio (MRQ)	2.30	8.36
Debt / Equity (MRQ)	0.19	0.50
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Moderna (MRNA) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Moderna (MRNA) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Moderna (MRNA) nor Revolution Medicines (RVMD) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
MRNA: --

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RVMD: --

Moderna (MRNA) vs. Revolution Medicines (RVMD): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Both look expensive on sales: Moderna (MRNA) at 45.55 sits in the upper P/S ratio quartile, and Revolution Medicines (RVMD) at 210.51 prices even higher, above its industry range.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max: 58.18
MRNA: 45.55
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD: 210.51
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Moderna (MRNA) at 11.58 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max: 13.53
MRNA: 11.58
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD: 17.31
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Moderna (MRNA) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Moderna (MRNA) and Revolution Medicines (RVMD)
Metric	MRNA	RVMD
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	45.55	210.51
P/B Ratio (MRQ)	11.58	17.31
Free Cash Flow Yield (TTM)	0.29%	-2.13%